Latest Prasugrel Stories
SOUTH SAN FRANCISCO, Calif., Aug. 24 /PRNewswire/ -- Portola Pharmaceuticals, Inc.
PARSIPPANY, N.J. and INDIANAPOLIS, Aug. 5 /PRNewswire-FirstCall/ -- Effient(TM) (prasugrel), a new antiplatelet medicine, is now available in pharmacies across the United States, Daiichi Sankyo, Inc. and Eli Lilly and Company (NYSE: LLY) announced today. The U.S.
SAN DIEGO, July 14 /PRNewswire/ -- With the recent FDA approval of the new P2Y12 inhibitor, prasugrel (Effient), Accumetrics, Inc. announces that its VerifyNow P2Y12 Test is not only able to assess response to Plavix(R), but also its newly approved competitor, Effient.
PARSIPPANY, N.J. and INDIANAPOLIS, July 10 /PRNewswire-FirstCall/ -- Daiichi Sankyo, Inc. and Eli Lilly and Company (NYSE: LLY) today announced that the U.S.
SOUTH SAN FRANCISCO, Calif., July 10 /PRNewswire/ -- Portola Pharmaceuticals, Inc.
Universal Definition of Myocardial Infarction provided jointly by leading international cardiology societies TOKYO and INDIANAPOLIS, May 21 /PRNewswire-FirstCall/ -- Investigators from the Phase III TRITON-TIMI 38 study applied the new classification system for the Universal Definition of Myocardial Infarction to the results of the study and showed that patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI) and taking prasugrel, as compared with...
Patients with peripheral artery disease (PAD) could benefit from taking aspirin. A new study reveals the medication may lower the risk of stroke in these patients.
TOKYO and INDIANAPOLIS, Ind., May 5 /PRNewswire-FirstCall/ -- A new substudy from 1,466 patients from the Phase III TRITON-TIMI 38 clinical trial showed that patients who took prasugrel and had a reduced function of the CYP2C19 gene did not have an increased risk of cardiovascular death, heart attack or stroke compared with those patients who had normal function.
Growth Will be Driven by Drugs from Eli Lilly/Daiichi Sankyo, AstraZeneca, and Schering-Plough, According to a New Report from Decision Resources WALTHAM, Mass., March 24 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, despite the patent expiries by 2012 of the two sales-leading therapies, new product launches will drive an increase of $4.6 billion in the overall coronary heart disease market by...
A Phase II Study Published in The Lancet of Fast-Tracked Antiplatelet Agent Showed No Increase in TIMI Major and Minor Bleeding and was Well Tolerated When Given With Standard Platelet Therapy KENILWORTH, N.J., March 12 /PRNewswire-FirstCall/ -- Results of a Schering-Plough Corporation (NYSE: SGP) Phase II trial of SCH 530348, a novel oral thrombin receptor antagonist (TRA), were published today in The Lancet and demonstrated that the investigational antiplatelet compound met its primary...